Alnylam Pharmaceuticals (ALNY) EBIT (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.95% |
| Dec 31, 2025 | -64.21% |
| Sep 30, 2025 | 2,371.63% |
| Jun 30, 2025 | -189.61% |
| Mar 31, 2025 | 117.19% |
| Dec 31, 2024 | -36.74% |
| Sep 30, 2024 | -258.20% |
| Jun 30, 2024 | 211.92% |
| Mar 31, 2024 | 62.69% |
| Dec 31, 2023 | -154.43% |
| Sep 30, 2023 | 193.05% |
| Jun 30, 2023 | -53.42% |
| Mar 31, 2023 | 20.57% |
| Dec 31, 2022 | 26.91% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -30.64% |
| Mar 31, 2022 | 24.58% |
| Dec 31, 2021 | -7.09% |
| Sep 30, 2021 | -24.30% |
| Jun 30, 2021 | 21.53% |